Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
News archive
News Archive Navigation
News Archive Navigation Language
February 2016
-
Rediscovering the power of nature’s exquisite complexity
Read how nature's medicine chest empowers our drug discovery chemists to advance biomedical research
-
Media ReleaseSandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEASandoz acquires rights to PF-06438179 (biosimilar infliximab) in the European Economic Area (EEA)* Sandoz plans to complete Phase III development program and file for registration in the EU…
-
Intractable tumor cells crippled
Functional genomics study reveals a potential approach for tackling glioblastoma, pancreatic cancer and other tumors.
-
Media ReleaseSandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastimSandoz' late-stage biosimilar pipeline gains momentum with sustained investment - five of 10 planned regulatory filings achieved Sandoz believes that the totality of evidence in its submission,…
-
Leveraging the liver’s ability to heal scarred tissue
A reversal in thinking about the reversibility of liver damage is changing the field of hepatology.
-
Featured NewsInnovation in practice: how we form partnerships in pharma
The Novartis Business Development and Licensing team is behind many of the partnerships that fuel our innovation.
-
Opening chemistry education to the world
Novartis taps MOOC technology to share chemistry education with the world
-
Neuroscientists restore cell-to-cell signaling and sociability in autism models
Team uncovers a potential therapeutic approach for patients deficient in a protein called Shank3.
-
Featured NewsHow digital technologies are creating a “new normal” for people living with COPD
Learn how Novartis is working with chronic obstructive pulmonary disease (COPD) patients to develop digital health technologies that help them find their “new normal.”
-
Novartis and Pfizer join forces to upend oncology dogma
Industry labs find that, contrary to earlier evidence, KRAS-driven tumors are not addicted to autophagy.
January 2016
-
Media ReleaseNovartis Foundation commemorates World Leprosy Day with its continued efforts to go the last mile toward elimination2016 marks 30 years of commitment by the Novartis Foundation to support people affected by leprosy and to end this ancient disease New strategy from the Novartis Foundation to accelerate…
-
Featured NewsNovartis 2015 Financial Results
Pagination
- ‹ Previous page
- 1
- …
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- …
- 151
- › Next page